Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1990-6-28
|
pubmed:abstractText |
Anorexia, cachexia, and resultant weight loss are major clinical problems in a substantial proportion of patients with advanced cancer. Effective means of alleviating these problematic symptoms are lacking. Extensive clinical data demonstrate a weight enhancing effect for the serotonin antagonist, cyproheptadine, in several clinical situations. In addition, sound basic research suggests that cyproheptadine may be helpful in patients with cancer anorexia/cachexia. Because of this, the authors performed a randomized, placebo-controlled, double-blinded clinical trial using cyproheptadine, 8 mg orally three times a day in 295 patients with advanced malignant disease. Patients assigned to cyproheptadine had less nausea (P = 0.02), less emesis (P = 0.11), more sedation (P = 0.07), and more dizziness (P = 0.01) than placebo patients. Patients' appetites, measured by serial patient-completed questionnaires, appeared to be mildly enhanced by cyproheptadine. Unfortunately, cyproheptadine did not significantly abate progressive weight loss in these patients with advanced malignant disease; patients assigned to cyproheptadine lost an average of 4.5 pounds per month compared to 4.9 pounds per month for patients assigned to a placebo (P = 0.72).
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0008-543X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
65
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2657-62
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2187585-Adult,
pubmed-meshheading:2187585-Aged,
pubmed-meshheading:2187585-Aged, 80 and over,
pubmed-meshheading:2187585-Anorexia,
pubmed-meshheading:2187585-Appetite,
pubmed-meshheading:2187585-Cachexia,
pubmed-meshheading:2187585-Cyproheptadine,
pubmed-meshheading:2187585-Double-Blind Method,
pubmed-meshheading:2187585-Eating Disorders,
pubmed-meshheading:2187585-Female,
pubmed-meshheading:2187585-Follow-Up Studies,
pubmed-meshheading:2187585-Humans,
pubmed-meshheading:2187585-Male,
pubmed-meshheading:2187585-Middle Aged,
pubmed-meshheading:2187585-Neoplasms,
pubmed-meshheading:2187585-Placebos,
pubmed-meshheading:2187585-Randomized Controlled Trials as Topic,
pubmed-meshheading:2187585-Weight Gain
|
pubmed:year |
1990
|
pubmed:articleTitle |
A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia.
|
pubmed:affiliation |
Alton Ochsner Medical Foundation CCOP, New Orleans, Louisiana.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|